The Microtubule Hypothesis of Antipsychotic Action: Converging Evidence That Dopamine Blockade Is Downstream of Cytoskeletal Normalization

Every antipsychotic drug tested to date modulates microtubule biology, yet no formal hypothesis hasproposed this as the primary therapeutic mechanism. Here I assemble converging evidence — spanningdirect tubulin binding, MAP2 expression changes, GSK-3β pathway inhibition, cytoskeletal genetics, andthe MAP6/STOP knockout mouse model — to argue that antipsychotic efficacy derives primarily fromnormalization of pathologically altered microtubule dynamics, with dopamine D2 receptor blockaderepresenting a pharmacologically prominent but therapeutically secondary effect. A newly constructedcomposite microtubule-modulating score integrating four independent mechanisms correlates positivelywith antipsychotic clinical efficacy (standardized mean difference, SMD; r = +0.49, n = 7), while D2receptor affinity correlates negatively with efficacy (r = −0.53). A controlled within-class analysis of CF3substituted phenothiazine/thioxanthene pairs (4/4 concordant) provides independent structuralpharmacological support. This hypothesis resolves three longstanding puzzles: (1) why clozapine, themost effective antipsychotic, has the weakest D2 affinity; (2) why 30–50% of patients are treatmentresistant to D2-blocking agents; and (3) why the MAP6/STOP knockout mouse — a purely cytoskeletalmodel — produces a complete schizophrenia phenotype including downstream dopamine dysregulation.The critical experiment — systematic nanoDSF screening of second-generation antipsychotics combinedwith a prospective clinical trial of MT-normalizing agents in “D2-responsive” patients — is now bothfeasible and urgently indicated.